{"schema_version":"secwatch.filing_event.v1","accession":"0001640334-22-001222","form_type":"8-K","ticker":"LEXX","cik":"0001348362","company_name":"Lexaria Bioscience Corp.","filed_at":"2022-06-09T23:59:59+00:00","discovered_at":"2026-05-14T18:04:00.335053+00:00","generated_at":"2026-06-25T03:05:34.922479+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexaria licenses DehydraTECH to AnodGen; pre-IND filed for CBD hypertension","bullets":["Lexaria subsidiary entered 5-year non-exclusive license with AnodGen for DehydraTECH in Europe, UK, Australia, NZ.","AnodGen will pay royalties on revenues from sales of DehydraTECH-infused powders.","Pre-IND meeting request filed with FDA for DehydraTECH-CBD for hypertension; target date July 30, 2022.","IND-enabling development ongoing; Lexaria expects to submit IND in late 2022 or early 2023.","HYPER-H21-4 study collects 24-hour BP, arterial stiffness, ECG, MRI, biomarkers, and other data."],"urls":{"canonical":"https://secwatch.observer/filing/0001640334-22-001222","json":"https://secwatch.observer/filing/0001640334-22-001222.json","markdown":"https://secwatch.observer/filing/0001640334-22-001222.md","text":"https://secwatch.observer/filing/0001640334-22-001222.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1348362/000164033422001222/0001640334-22-001222-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1348362/000164033422001222/lxrp_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T03:05:34.922479+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}